3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Q2 FY18 Earnings Presentation
17 slides from 3b Blackbio Dx's earnings presentation, Nov 11, 2017
Slide 1: Cover letter to BSE
cs sc KILPEST INDIA LIMITED REGD. OFFICE & FACTORY : 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 (INDIA) Tel : (91-755) 2586536, 2586537, 2586439 FAXNO. : (91-755) 2580438 Email : kilpest@bsnl.in visit us at : www.kilpest.com kilpestbpl@yahoo.co.in CIN : L24211MP1972PLC001131 Ref. No.P-66/ No
Slide 2: Investor Presentation November 2017
Farmers trusted Agro-input partner for 44 years Reliable & affordable healthcare diagnostics solutions INVESTOR PRESENTATION NOVEMBER 2017
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to
Slide 4: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides - 70 • Bio pesticide - 07 • Antibacterials - 01 • Bio fungicide - 01 • Fungicides - 15 • Bio fertilizers - 05 • Herbicides - 11 • Bio nematicides - 01 • Public Health - 11 • Public Health - 02 • Microferti
Slide 5: Business Overview and Strengths
Business Overview and Strengths Experienced team & state of art facility located in center of India- with GST implementation this should give a boost to the company • 44yrs old Pesticide Formulation Company, well established in central India, strong brand equity in central India especially in Madhya
Slide 6: Financial Performance: Key Highlights
Financial Performance : Key Highlights Q2FY18, KILPEST (Consolidated) Q2 FY18 Q2FY17 FY17 Q2 FY18, 132.96 28.34% 86.30% 786.80 Net sales (net of Excise duty) 786.80 613.05 1616.33 Q2FY17, 613.05 Profit before tax 175.25 87.19 139.69 Q2FY17, Profit after tax 132.96 71.37 113.18 71.37 Paid up Equity s
Slide 7: Present Market Overview
Present Market Overview The half yearly sales has been better despite bad/unevenly spread monsoon, due to Government sales for Public Health for 25 million Rupees. As was mentioned in earlier update. In 3rd quarter also Government order worth 10-15 million Rupees are expected from Government for Pub
Slide 8: Financial Highlights- 3B BlackBio Biotech (Q2 FY18)
Financial Highlights- 3B BlackBio Biotech (Q2 FY18) Q2 FY18, Q2 FY18, 192.18% 233.86% 134.48 206.92 Q2 FY17, Q2 FY17, 40.28 70.82 Revenue EBITDA Q2 FY18, Q2 FY18, 88.52 120.35 275.98% 300.18% Q2 FY17, Q2 FY17, 32.01 22.12 Rs. In Lakhs PBT PAT BCR ABL I JAK 2 I PML RARA I KRAS I HLA B27 I MDR TB I H1
Slide 9: Industry Potential- Molecular Diagnostics
Industry Potential- Molecular Diagnostics • The global IVD Market US$ 54.7 billion in the year 2015 (CAGR of 5-6%)1 Highest Growth Rate • Molecular Diagnostic Market US$ 7 billion (CAGR of 10-15%)2 • Indian diagnostics industry was around Rs. 377 billion in 2014-2015 and will continue to grow by a C
Slide 10: Demand drivers for the Indian Diagnostic Industry
Demand drivers for the Indian Diagnostic Industry • Increased focus on advanced diagnostics • changing costs and quality of healthcare, • rising medical tourism, • evolution of disease profiles, • technology as a driving force, • increase in evidence-based treatments / Drug response monitoring • cha
Slide 11: Molecular Diagnostics
Molecular Diagnostics • The process of identifying a disease by studying molecules, such as proteins, DNA, and RNA, in a tissue or fluid. • Molecular diagnostics is a technique used to analyze biological markers in the genome and proteome—the individual’s genetic code and how their cells express the
Slide 12: Winning Strategy
Winning Strategy • Proprietary kits designed, developed & validated in-house • Well accepted assays across wide customer base PAN India • Continuous R&D initiatives for International quality product • Wide range of Diagnostic kits- Infectious, Oncology & Genetics • Import substitution with price adv
Slide 13: New Customers added in Q2 2017-18
New Customers added in Q2 2017-18 • Leading Diagnostic lab added as customer in Pune. • Multi-Speciality hospital added in Kolkata • Leading Muti-Speciality hospital added in Hyderabad • Multi-Speciality hospital added in Dehradun. • Diagnostic lab added in Kanpur, Patna and Coimabatore • Leading di
Slide 14: Products in Pipeline
Products in Pipeline • Below 3 assays are ready, requiring final validation will be launched in Q3 FY18- • EGFR Mutation Analysis(A major cause of lung cancer) • AML/ALL Panel ( Leukemia causing mutations) • Coagulation Prognostic Panel • Factor V Mutation Detection- specific gene mutation that resu
Slide 15: PCR based Molecular Diagnostic Kit Range
PCR based Molecular Diagnostic Kit Range Genetics & TRUPCR® BCR-ABL Qualitative Kit – M m µ Detection and differentiation of BCR-ABL major (M), minor (m) and micro (µ) transcripts Oncology TRUPCR® BCR-ABL Quantitative Kit – M m µ Detection, differentiation and quantitation of BCR-ABL major (M), mino
Slide 16: PCR based Molecular Diagnostic Kit Range (continued)
Drug Resistance TRUPCR® Rifampicin Resistant MTB Detection Kit Extraction of MTBC DNA from any sample type, detection of MTB & Rifampicin resistance mutations Coagulation TRUPCR® Factor V Leiden mutation. Detection of Factor V Leiden mutation on real-time PCR Prognostic Panel Blood-borne TRUPCR® HBV
Slide 17: Contact: Kilpest India Limited and 3B BlackBio Biotech India Limited
For further information, please contact: KILPEST INDIA LIMITED 3B BLACKBIO BIOTECH INDIA LIMITED 7-C Industrial Area , Govindpura, Bhopal- 462023[M.P.] INDIA 7-C Industrial Area , Govindpura, Bhopal- 462023 [M.P.] INDIA Phone :: +91-755-2586536 Phone :: +91-755-4077847 Fax :: +91-755-2580438 Fax ::